Clinical Trials Directory

Trials / Completed

CompletedNCT03193138

CardioTOxicity Induced by andRogeNICS and Their Antagonists (TORNICS)

Cardiotoxicity of Androgenic Agonists and Antagonists in the National French Pharmacovigilance Database and EudraCT Database

Status
Completed
Phase
Study type
Observational
Enrollment
3,096 (actual)
Sponsor
Groupe Hospitalier Pitie-Salpetriere · Academic / Other
Sex
Male
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

Anti-androgenic therapies relying on peripheral and/or central blockade for the treatment of prostate cancer seems to have an impact on the cardio-vascular system. This study investigates reports of cardiovascular toxicities for treatment including Anatomical Therapeutic Chemical (ATC) classification: sex hormones (G03), hypothalamic hormones (H01C) and sex hormones used in treatment of neoplastic diseases (L02) in the French pharmacovigilance database and European Clinical Trials (EudraCT) database.

Detailed description

Hormone replacement therapies and contraceptive pills are responsible of a wide range of cardio-vascular side effects, particularly thrombo-embolic disorders and ischemic heart disease. The difference of incidence and type of cardio-vascular events between men and women are strongly related to sex hormones. Androgenic agonists and antagonists are used in various indication including prostate cancer or hormone replacement therapies. This study investigates the main characteristics of patients affected by cardiovascular side effects (of which ventricular arrhythmia's, QT prolongation and Torsade de Pointe) imputed to drugs classified as G03, H01C and L02 according to ATC. A causality assessment according to both Begaud's method and the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) is systematically applied.

Conditions

Interventions

TypeNameDescription
DRUGHormonal therapies: G03, H01C and L02 in the ATC classificationHormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification

Timeline

Start date
2017-06-07
Primary completion
2017-06-21
Completion
2017-06-21
First posted
2017-06-20
Last updated
2019-09-25

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03193138. Inclusion in this directory is not an endorsement.